// App-Quantinova.ai

P442 : Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience

Researchers

Presenter

  • B. Feagan

Principal Investigators

  • F. Bhayat

  • J.M. Khalid

  • W. Palo

  • A. Blake

  • M. Shetzline

  • S. Travis

Medical Centers

  • Robarts Research Institute, University of Western Ontario, Clinical Trials, London, ON, Canada

  • Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

  • Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States

  • Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom

  • Takeda Pharmaceuticals International Co., Global Statistics, Cambridge, United States

  • University of Oxford, Translational Gastro-Intestinal Unit- Nuffield Department of Medicine, Oxford, United Kingdom

Locations

  • Canada

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved